Rao Yi's Gritgen Therapeutics Unveils Novel AAV Vector to Break Kidney Gene Therapy Delivery Bottlenecks

Gritgen Therapeutics Co., Ltd., the biotech company founded by renowned biologist Professor Rao Yi, has unveiled a novel adeno-associated virus (AAV) vector with promising new preclinical data. The engineered vector demonstrates exceptional kidney-targeting capabilities in both rodent and nonhuman primate models, potentially breaking through a long-standing delivery bottleneck in kidney gene therapy and laying the foundation for a therapeutic platform to treat genetic renal diseases.

Kidney disease represents an emerging frontier for cell and gene therapy. Approximately 30% of chronic kidney diseases stem from single-gene defects—including polycystic kidney disease, Alport syndrome, and cystinuria—conditions that could be addressed through precision medicine interventions. However, the kidney's complex architecture and diverse cell types have made it difficult for conventional AAV vectors to achieve efficient, specific transduction following intravenous administration. More critically, many vectors that perform well in mouse models fail to replicate similar results in nonhuman primates, which more closely resemble human physiology.

Gritgen's proprietary AAV capsid variant addresses this industry pain point with three key breakthroughs.

Cross-species efficient transduction: Following a single intravenous injection, the vector achieved infection efficiency exceeding 90% in the proximal tubules of the mouse kidney cortex—far surpassing wild-type AAV9, which demonstrated less than 40% efficiency. In nonhuman primate kidneys, the vector proved equally robust, successfully transducing more than 60% of proximal tubule cells and approximately 40% of distal tubule cells. This achievement positions it as potentially the first vector to simultaneously achieve efficient dual-segment transduction of both proximal and distal tubules in primate kidneys via intravenous administration.

Multi-cell-type precise targeting: Studies confirm the vector's transduction precisely covers the core functional regions responsible for reabsorption and electrolyte regulation, providing an ideal delivery tool for treating hereditary kidney diseases that affect multiple tubule segments.

Significantly improved production yield: In HEK293 cell triple-plasmid transfection systems, the novel vector demonstrated markedly higher yields than wild-type AAV9, creating favorable conditions for scale-up manufacturing and cost control in subsequent development.

This R&D breakthrough not only fills a gap in current kidney-targeted delivery technology but also offers new hope for hundreds of millions of kidney disease patients worldwide.

In terms of overall corporate development, Gritgen has leveraged its founding team's years of experience in gene therapy to build an efficient AAV vector technology platform, with a pipeline spanning hematological, neurological, and metabolic disease areas. The company's product portfolio covers both rare and common diseases.

In its early stages, Gritgen focused on liver-targeted gene delivery technology, launching GS1191 for hemophilia A—China's first AAV gene therapy product to receive Investigational New Drug (IND) approval and advance into Phase III clinical trials. The product has accumulated data from more than 50 patients, achieving favorable safety and durable efficacy at just 5% of the clinical dose used by the international best-in-class product, and has received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA).

Additionally, the company's GS1168 (for phenylketonuria) and GS1196 (for hereditary angioedema) programs have achieved breakthroughs in therapeutic mechanism and expression efficiency, with potential to become first-in-class gene therapy products globally.

As society ages, neurodegenerative diseases such as Alzheimer's and Parkinson's impose growing burdens on families and healthcare systems. Gritgen has responded by leveraging its proprietary blood-brain barrier-penetrating AAV capsid to achieve a balanced pipeline spanning both rare diseases and common central nervous system conditions.

To support its R&D and manufacturing needs, the company operates a GMP-compliant production facility exceeding 8,500 square meters, encompassing plasmid and AAV production. During development of its lead product, Gritgen pioneered China's first 200-liter suspended HEK293 cell process development, establishing a solid foundation for subsequent manufacturing scale-up.